Phaseline

Targets › SNCA

SNCA (Alpha-synuclein): drug programs, companies and trials

6 programs from 6 companies in 11 trials: 6 Phase 2, 4 Phase 1, 1 Phase 3; Neurology, Other; next expected readout Jan 2027.

Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. (UniProt, P37840)

Open in Phaseline: the race on SNCA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RochePrasinezumab
Alpha-synuclein binding agent
SNCAPhase 3Parkinson's Disease; Parkinsons DiseaseJun 2029
Teva Branded Pharmaceutical Products R&DTEV-56286
alpha-synuclein aggregation inhibitor
SNCAPhase 2Multiple System Atrophy; Healthy VolunteersJan 2027
AC ImmuneACI-7104.056
Adjuvanted alpha-synuclein peptide conjugate vaccine
SNCAPhase 2Parkinson DiseaseJun 2028
XingImaging[¹⁸F]MK-0947
alpha-synuclein (ASYN) PET imaging agent
SNCAPhase 1Parkinsons Disease (PD)Sep 2027
University of ShizuokaMF1
α-synuclein inhibitor
SNCAPhase 1Healthy Adult MaleSep 2028
Regeneron PharmaceuticalsALN-SNCA
SNCA mRNA inhibitor (siRNA)
SNCAPhase 1Parkinsons DiseaseJun 2029

Conditions

Parkinson's Disease (3) Multiple System Atrophy (2) Parkinsons Disease (2) Healthy Volunteers (1) Healthy Adult Male (1) Parkinson Disease (1) Parkinsons Disease (PD) (1)

Modalities

small molecule (4), protein or peptide (1), antibody (1)

Companies

Teva Branded Pharmaceutical Products R&D (1) University of Shizuoka (1) AC Immune (1) Regeneron Pharmaceuticals (1) Roche (1) XingImaging (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.